Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis

Inclusion Criteria: * Patients willing to participate, obtained written informed consent. * Male or female patients ≥ 18 years. * Clinically confirmed diagnosis of mild to moderate Actinic keratosis (AK) of the face including the forehead (excluding eyelids, lips and mucosa) and/or the bald scalp. * Presence of at least 4 but not more than 8 isolated (i.e. discrete and quantifiable) AK lesions located in a contiguous treatment area (TA) on the face and/or bald scalp of 25 square-cm. * AK lesions of the TA must be clinically typical AK lesions of Olsen grade I and/or grade Olsen grade II. * Ability to follow study instructions and likely to complete all study requirements. Exclusion Criteria: * TA is within 5 cm of an incompletely healed wound or infected area of the skin. * Patients not willing to abstain from sunbathing (including solarium) or any outdoor activities with intensive sun exposure without taking appropriate measures to protect the treatment areas during the study. * Patients with a tendency to manipulate skin parts e.g. scratching. * Pregnant or breast-feeding patients. * Patients currently or within the past 4 weeks participating in another clinical study. * Any previous randomization into this clinical study. * Any suspicion of current drug and/or alcohol abuse. * Patient is institutionalized because of legal or regulatory order. * Dependency (as an employee or relative) to the sponsor/responsible CRO or investigator. * Any condition that in the opinion of …